The Pharmalot View

The Pharmalot View Ed Silverman

STAT Plus: Forget about an international pricing index for drugs. Cost-effectiveness is a better bargain

The Pharmalot View Ed Silverman

STAT Plus: Tweet this: Gottlieb’s leaving, and so is FDA’s highly effective communicator

The Pharmalot View Ed Silverman

STAT Plus: Prepare for grilling: 7 questions for 7 pharma execs who’ll testify before Congress about prices

The Pharmalot View Ed Silverman

STAT Plus: The military pushed it for the battlefield. The FDA went along. Is the newest opioid any better?

The Pharmalot View Ed Silverman

STAT Plus: The list price is not right: Trump’s plan to force pharma to advertise prices is misguided

The Pharmalot View Ed Silverman

STAT Plus: One of the world’s largest drug makers is paying docs again — and patients are the worse off

The Pharmalot View Ed Silverman

STAT Plus: From zero to hero: J&J CEO praises Trump one year after chastising him

The Pharmalot View Ed Silverman

STAT Plus: When modest is actually excessive: AstraZeneca spins its price hikes

The Pharmalot View Ed Silverman

STAT Plus: He can shame Pfizer and others, but Trump doesn’t have a practical way to lower drug prices

The Pharmalot View Ed Silverman

STAT Plus: Novartis’ tone-deaf response to Michael Cohen: troubling, but not surprising

The Pharmalot View Ed Silverman

STAT Plus: Sanofi scandal in the Philippines could spread dangerous mistrust of vaccines

The Pharmalot View Ed Silverman

STAT Plus: The Pentagon wants to approve drugs for the battlefield. Here’s why that’s dangerous

The Pharmalot View Ed Silverman

STAT Plus: California just passed a law to rein in drug prices. Here’s why it’s unlikely to make much difference

The Pharmalot View Ed Silverman

Here’s how a loophole in a transparency law can distort medical practices

The Pharmalot View Ed Silverman

STAT Plus: This pharma CEO won praise for his ‘social contract’ with the public. But his latest move could shred that pledge

The Pharmalot View Ed Silverman

STAT Plus: At $475,000, new cancer drug raises thorny questions about drug pricing — and value

The Pharmalot View Ed Silverman

STAT Plus: Drug makers deserve to be publicly shamed for thwarting competition from generics

The Pharmalot View Ed Silverman

STAT Plus: The art of the deal? Why a money-back guarantee for drugs is a bad idea

The Pharmalot View Ed Silverman

STAT Plus: If drug companies are really ‘getting away with murder,’ Trump may be about to grant them a pardon

The Pharmalot View Ed Silverman

STAT Plus: It’s time to make it legal for Americans to order prescription drugs from abroad

The Pharmalot View Ed Silverman

STAT Plus: US taxpayers are funding a Zika vaccine. Let’s make sure US patients can afford it

The Pharmalot View Ed Silverman

STAT Plus: The Trump administration could bring down drug prices. But it would take guts

The Pharmalot View Ed Silverman

STAT Plus: Dear Scott Gottlieb: Add new warnings to Paxil labels. You may save a life

The Pharmalot View Ed Silverman

STAT Plus: How a $37,000-a-year medicine sets a good model for drug pricing

The Pharmalot View Ed Silverman

STAT Plus: Here’s one drug safety rule the FDA should enact — quickly

The Pharmalot View Ed Silverman

STAT Plus: Dear Mr. President: Your view of the FDA is misguided. Here’s why

The Pharmalot View Ed Silverman

STAT Plus: Dear Vice President Pence: Stop peddling false hopes to dying patients

The Pharmalot View Ed Silverman

STAT Plus: Pharma trade group vows to review membership criteria, but is this an empty promise?

The Pharmalot View Ed Silverman

STAT Plus: Dear President Trump: Your big idea on drug pricing is half-baked